CONTEXT: Pheochromocytomas and paragangliomas (PPGLs) are diagnosed earlier in patients with hereditary than sporadic disease. Whether other factors influence age at diagnosis is unclear. OBJECTIVE: We examined ages at which PPGLs were diagnosed according to different catecholamine phenotypes and locations of tumors. DESIGN & SETTING: Retrospective multicenter study. PATIENTS: Patients with PPGLs included 172 with and 183 without identified germline mutations or hereditary syndromes. BIOCHEMICAL MEASUREMENTS: Differences in plasma concentrations of metanephrine, a metabolite of epinephrine, were used to distinguish epinephrine-producing tumors from those lacking epinephrine production. RESULTS: Patients with epinephrine-producing tumors were diagnosed 11 yr later (P < 0.001) than those with tumors lacking appreciable epinephrine production. Among patients without evidence of a hereditary condition, those with and without epinephrine-producing tumors had respective mean ± se ages of 50 ± 2 and 42 ± 2 yr (P < 0.001) at diagnosis. Patients with multiple endocrine neoplasia type 2 and neurofibromatosis type 1, all with epinephrine-producing tumors, were similarly diagnosed with disease at a later age than patients with tumors that lacked appreciable epinephrine production secondary to mutations of von Hippel-Lindau and succinate dehydrogenase genes (40 ± 2 vs. 31 ± 1 yr, P < 0.001). Among the latter patients, those with multifocal tumors were diagnosed earlier than those with solitary tumors (19 ± 3 vs. 34 ± 2 yr, P < 0.001). CONCLUSIONS: The variations in ages at diagnosis associated with different tumor catecholamine phenotypes and locations suggest origins of PPGLs from different chromaffin progenitor cells with variable susceptibility to disease causing mutations. Different optimal age cut-offs for mutation testing are indicated for patients with and without epinephrine-producing tumors (44-49 vs. 30-35 yr, respectively).
CONTEXT: Pheochromocytomas and paragangliomas (PPGLs) are diagnosed earlier in patients with hereditary than sporadic disease. Whether other factors influence age at diagnosis is unclear. OBJECTIVE: We examined ages at which PPGLs were diagnosed according to different catecholamine phenotypes and locations of tumors. DESIGN & SETTING: Retrospective multicenter study. PATIENTS: Patients with PPGLs included 172 with and 183 without identified germline mutations or hereditary syndromes. BIOCHEMICAL MEASUREMENTS: Differences in plasma concentrations of metanephrine, a metabolite of epinephrine, were used to distinguish epinephrine-producing tumors from those lacking epinephrine production. RESULTS:Patients with epinephrine-producing tumors were diagnosed 11 yr later (P < 0.001) than those with tumors lacking appreciable epinephrine production. Among patients without evidence of a hereditary condition, those with and without epinephrine-producing tumors had respective mean ± se ages of 50 ± 2 and 42 ± 2 yr (P < 0.001) at diagnosis. Patients with multiple endocrine neoplasia type 2 and neurofibromatosis type 1, all with epinephrine-producing tumors, were similarly diagnosed with disease at a later age than patients with tumors that lacked appreciable epinephrine production secondary to mutations of von Hippel-Lindau and succinate dehydrogenase genes (40 ± 2 vs. 31 ± 1 yr, P < 0.001). Among the latter patients, those with multifocal tumors were diagnosed earlier than those with solitary tumors (19 ± 3 vs. 34 ± 2 yr, P < 0.001). CONCLUSIONS: The variations in ages at diagnosis associated with different tumorcatecholamine phenotypes and locations suggest origins of PPGLs from different chromaffin progenitor cells with variable susceptibility to disease causing mutations. Different optimal age cut-offs for mutation testing are indicated for patients with and without epinephrine-producing tumors (44-49 vs. 30-35 yr, respectively).
Authors: Patrick J Pollard; Mona El-Bahrawy; Richard Poulsom; George Elia; Pip Killick; Gavin Kelly; Toby Hunt; Rosemary Jeffery; Pooja Seedhar; Julian Barwell; Farida Latif; Michael J Gleeson; Shirley V Hodgson; Gordon W Stamp; Ian P M Tomlinson; Eamonn R Maher Journal: J Clin Endocrinol Metab Date: 2006-09-05 Impact factor: 5.958
Authors: Yuejuan Qin; Li Yao; Elizabeth E King; Kalyan Buddavarapu; Romina E Lenci; E Sandra Chocron; James D Lechleiter; Meghan Sass; Neil Aronin; Francesca Schiavi; Francesca Boaretto; Giuseppe Opocher; Rodrigo A Toledo; Sergio P A Toledo; Charles Stiles; Ricardo C T Aguiar; Patricia L M Dahia Journal: Nat Genet Date: 2010-02-14 Impact factor: 38.330
Authors: Susanne Schlisio; Rajappa S Kenchappa; Liesbeth C W Vredeveld; Rani E George; Rodney Stewart; Heidi Greulich; Kristina Shahriari; Nguyen V Nguyen; Pascal Pigny; Patricia L Dahia; Scott L Pomeroy; John M Maris; A Thomas Look; Matthew Meyerson; Daniel S Peeper; Bruce D Carter; William G Kaelin Journal: Genes Dev Date: 2008-03-11 Impact factor: 11.361
Authors: Zoran Erlic; Lisa Rybicki; Mariola Peczkowska; Henriette Golcher; Peter H Kann; Michael Brauckhoff; Karsten Müssig; Michaela Muresan; Andreas Schäffler; Nicole Reisch; Matthias Schott; Martin Fassnacht; Giuseppe Opocher; Silke Klose; Christian Fottner; Flavio Forrer; Ursula Plöckinger; Stephan Petersenn; Dimitry Zabolotny; Oleg Kollukch; Svetlana Yaremchuk; Andrzej Januszewicz; Martin K Walz; Charis Eng; Hartmut P H Neumann Journal: Clin Cancer Res Date: 2009-10-13 Impact factor: 12.531
Authors: Christopher J Ricketts; Julia R Forman; Eleanor Rattenberry; Nicola Bradshaw; Fiona Lalloo; Louise Izatt; Trevor R Cole; Ruth Armstrong; V K Ajith Kumar; Patrick J Morrison; A Brew Atkinson; Fiona Douglas; Steve G Ball; Jackie Cook; Umasuthan Srirangalingam; Pip Killick; Gail Kirby; Simon Aylwin; Emma R Woodward; D Gareth R Evans; Shirley V Hodgson; Vicky Murday; Shern L Chew; John M Connell; Tom L Blundell; Fiona Macdonald; Eamonn R Maher Journal: Hum Mutat Date: 2010-01 Impact factor: 4.878
Authors: G Eisenhofer; C D Vocke; A Elkahloun; T-T Huynh; T Prodanov; J W M Lenders; H J Timmers; J N Benhammou; W M Linehan; K Pacak Journal: Horm Metab Res Date: 2012-03-21 Impact factor: 2.936
Authors: Thomas G Papathomas; Diederik P D Suurd; Alfred K Lam; Ronald R de Krijger; Karel Pacak; Arthur S Tischler; Menno R Vriens Journal: Endocr Pathol Date: 2021-01-12 Impact factor: 3.943
Authors: Roland Därr; Jacques W M Lenders; Lorenz C Hofbauer; Bernd Naumann; Stefan R Bornstein; Graeme Eisenhofer Journal: Ther Adv Endocrinol Metab Date: 2012-02 Impact factor: 3.565